Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis

Introduction The fully-human monoclonal anti-interleukin (IL)-1β antibody canakinumab may inhibit the production of inflammatory mediators in patients with coronavirus disease 2019 (COVID-19) and the hyperinflammatory response potentially leading to acute respiratory distress syndrome. Objectives Th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of immunopathology and pharmacology 2021-12, Vol.35, p.20587384211059675-20587384211059675, Article 20587384211059675
Hauptverfasser:	Mastroianni, Antonio, Greco, Sonia, Chidichimo, Luciana, Urso, Filippo, Greco, Francesca, Mauro, Maria V, Vangeli, Valeria
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - immunology Biomarkers - blood Coronaviruses COVID-19 COVID-19 - complications COVID-19 - epidemiology COVID-19 - immunology COVID-19 - therapy Dose-Response Relationship, Drug Female Humans Immunology Inflammation Inflammation Mediators - blood Interleukin-1beta - antagonists & inhibitors Interleukin-1beta - immunology Italy - epidemiology Life Sciences & Biomedicine Male Mechanical ventilation Middle Aged Monitoring, Immunologic - methods Monoclonal antibodies Original Outcome and Process Assessment, Health Care Pathology Patient Selection Patients Pharmacology & Pharmacy Respiration, Artificial - methods Respiration, Artificial - statistics & numerical data Respiratory distress syndrome Respiratory failure Retrospective Studies SARS-CoV-2 Science & Technology Standard of care Time-to-Treatment Ventilation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!